Elsevier

Vaccine

Volume 11, Issue 6, 1993, Pages 679-681
Vaccine

Paper
Comparison of the nucleotide and deduced amino acid sequences of the structural protein genes of the yellow fever 17DD vaccine strain from Senegal with those of other yellow fever vaccine viruses

https://doi.org/10.1016/0264-410X(93)90317-QGet rights and content

Abstract

The nucleic acid and deduced amino acid sequences of the structural proteins of the 17DD vaccine strain of yellow fever (YF) virus originating from Senegal are compared with those published for other vaccine strains of YF virus. Even though the 17D-204 and 17DD substrains of 17D diverged at passage 195 of 17D, they show a very high degree of nucleotide (99.5%) and amino acid (99.5%) homology over this region. The sequences are discussed with respect to monoclonal antibodies that can distinguish between 17DD and 17D-204 substrains of YF vaccines.

References (14)

There are more references available in the full text version of this article.

Cited by (17)

  • Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice

    2014, Virology
    Citation Excerpt :

    Currently, substrains 17D-204, 17D-213, and 17DD are used for vaccine manufacturing. Although genetically distinct, all three substrains are immunogenic and efficacious, with amino acid substitutions likely responsible for attenuation (dos Santos et al., 1995; Jennings et al., 1993; Lang et al., 1999). A single dose of vaccine confers life-long protective immunity; therefore, a booster dose is not needed in most cases (Gotuzzo et al., 2013; Patel and Simons, 2013).

  • Yellow fever vaccine

    2012, Vaccines: Sixth Edition
  • Comprehensive analysis of T cell epitope discovery strategies using 17DD yellow fever virus structural proteins and BALB/c (H2<sup>d</sup>) mice model

    2008, Virology
    Citation Excerpt :

    The 17D, 17D-213, and 17DD, YF strains used for human vaccination are products of multiple passages of the virulent parental Asibi virus (Galler et al., 1997). The molecular basis of the attenuation has been identified, and all the vaccine strains have been shown to differ from the wild-type virus in a few amino acids (dos Santos et al., 1995; Galler et al., 1997; Jennings et al., 1993; Post et al., 1992). The strain 17D has been successfully used worldwide for more than 65 years.

  • Yellow fever vaccine

    2008, Vaccines
View all citing articles on Scopus
View full text